The British–Swedish pharmaceutical company, Astrazeneca, announced a partnership with KM Biologics in Kumamoto City for the domestic formulation of new coronavirus vaccines. Vaccines of Astrazeneca will be imported to Japan from the U.S. and Europe in a fully-prepared form, except for 9,000 doses that need formulations and fills. KM Biologics will use its facility to produce flu vaccines for those tasks and continue its vaccine development against the new coronavirus. Source: KM biologics / Kumanichi
Disclaimer: Fukuoka Now posts summaries of Kyushu area news for those who cannot read Japanese. These are mostly summaries of publicly posted news from the Japanese media. Errors might occur during translation, those are ours. Images are sourced separately and are for illustrative purposes only. Use this form to send feedback. Please share links to this page, it helps us.